Aroa Biosurgery Limited
Aroa Biosurgery Limited
- P/E ratio
- 42.08
Your view on ARX.AX
Overview
What the company does, where it operates, and who runs it.
About Aroa Biosurgery Limited
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Brian Ward
- Headquarters
- 64 Richard Pearse Drive, Auckland, AU, NZ
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Brian Ward
- Headquarters
- 64 Richard Pearse Drive, Auckland, AU, NZ
Aroa Biosurgery Limited operates as a regenerative medicine company dedicated to the development, production, and global distribution of medical solutions for wound and tissue repair. The firm innovatively utilizes extracellular matrix (ECM) technology, with its market presence spanning the United States and international territories.
Its product line encompasses Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold, tailored for managing both acute and chronic wounds.
Additionally, the company offers Myriad Matrix, an engineered ECM device designed for soft tissue repair, reinforcement, and complex wound treatment, along with Myriad Morcells, a powdered version of Myriad Matrix serving similar soft tissue and complex wound applications.
Rounding out its offerings are Reinforced Bioscaffolds, a specialized surgical product employed in ventral hernia repair and abdominal wall reconstruction. Founded in 2007, Aroa Biosurgery Limited is headquartered in Auckland, New Zealand.
Stock Data
Price chart, volume, and trading data.
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Aroa Biosurgery Limited from FRC's valuation model, read against the market price. ARX.AX last traded at AUD 0.56, 42.1× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Aroa Biosurgery Limited. Starting points for Aroa Biosurgery Limited: P/E 42.1, EPS AUD 0.01, beta 0.85 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Aroa Biosurgery Limited. Aroa Biosurgery Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Aroa Biosurgery Limited. Trailing twelve-month EPS for Aroa Biosurgery Limited stands at AUD 0.01. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Earnings Estimate
| EPS | Current QtrJun 2026 | Next QtrSep 2026 | Current YearFY Mar 2027 | Next YearFY Mar 2028 |
|---|---|---|---|---|
| Avg. estimate | AUD 0.00 | AUD 0.00 | AUD 0.01 | AUD 0.03 |
| Low estimate | AUD 0.00 | AUD 0.00 | AUD 0.01 | AUD 0.02 |
| High estimate | AUD 0.00 | AUD 0.00 | AUD 0.02 | AUD 0.04 |
| No. of analysts | 0 | 1 | 3 | 3 |
| Year-ago EPS | AUD 0.011 | −AUD 0.001 | AUD 0.011 | — |
| Growth | — | — | — | — |
1Year-ago EPS includes one-time items; growth not shown.
Revenue Estimate
| Revenue | Current QtrJun 2026 | Next QtrSep 2026 | Current YearFY Mar 2027 | Next YearFY Mar 2028 |
|---|---|---|---|---|
| Avg. estimate | AUD 53.98M | AUD 45.34M | AUD 98.31M | AUD 112.80M |
| Low estimate | AUD 53.98M | AUD 45.34M | AUD 96.79M | AUD 108.29M |
| High estimate | AUD 53.98M | AUD 45.34M | AUD 99.89M | AUD 116.52M |
| No. of analysts | 1 | 1 | 3 | 3 |
| Year-ago revenue | AUD 20.69M | AUD 41.08M | AUD 92.28M | — |
| Growth | +160.8% | +10.4% | +6.5% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 20, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Aroa Biosurgery Limited. Aroa Biosurgery Limited has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| CMB.AXCambium Bio Limited | Healthcare | Biotechnology | — | ||
| OCC.AXOrthocell Limited | Healthcare | Biotechnology | — | ||
| OSX.AXOsteopore Limited | Healthcare | Medical - Instruments & Supplies | — | ||
| PNV.AXPolyNovo Limited | Healthcare | Medical - Devices | — | ||
| TRP.AXTissue Repair Ltd | Healthcare | Biotechnology | — | ||
| TTX.AXTetratherix Ltd. | Healthcare | Biotechnology | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| CBLLCeriBell, Inc. | Healthcare | NASDAQ | $995.3M | ||
| CERSCerus Corporation | Healthcare | NASDAQ | $391.8M | ||
| CGHCCapital Group Holdings, Inc. | Healthcare | OTC | $9,220 | ||
| CHEOFCochlear Limited | Healthcare | OTC | $8.9B | ||
| CHEOYCochlear Limited | Healthcare | OTC | $9.2B | ||
| CHYPFHealth Logic Interactive Inc. | Healthcare | OTC | $165,839 | ||
| CLLKFBICO Group AB (publ) | Healthcare | OTC | $123.3M | ||
| CLPTClearPoint Neuro, Inc. | Healthcare | NASDAQ | $247.1M | ||
| CLVSFCellaVision AB (publ) | Healthcare | OTC | $378.0M | ||
| CMP.AXCompumedics Limited | Healthcare | ASX | — | ||
| CNMDCONMED Corporation | Healthcare | NYSE | $1.4B | ||
| CNVIFConavi Medical Corp. | Healthcare | OTC | $20.7M | ||
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Aroa Biosurgery Limited. Coverage tracks Aroa Biosurgery Limited within Medical - Devices (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Aroa Biosurgery Limited.